All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cymerus mesenchymal stem cell
Therapeutic Area: Podiatry Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Details:
Cynata plans to undertake a clinical trial of its Cymerus MSC product in patients with diabetic foot ulcers based on this solid pre-clinical foundation and utilising the TekCyte technology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Diperoxochloric Acid
Therapeutic Area: Podiatry Product Name: WOXheal
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
WOXheal has dual mechanism of action, i.e. it has functional antibacterial action against Gram positive and gram negative bacteria and it also promotes growth of fibroblast cells, thereby yielding complete wound closure.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SkinTE
Therapeutic Area: Podiatry Product Name: SkinTE
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
Details:
The data show a statistically significant difference favoring PolarityTE’s autologous skin construct, SkinTE, in the primary endpoint of wounds closed at 12 weeks, and in percent area reduction of wounds at each time point measured.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TTAX01
Therapeutic Area: Podiatry Product Name: TTAX01
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
Company's first biologic license application (BLA) candidate TTAX01 to enter Investigational New Drug (IND) Phase 3 Trials for Diabetic Foot Ulcer (DFU) indication as first biologic product to seek FDA approval for complex Wagner Grade 3 and 4 DFUs .
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
